Table 1

Residents of the Reggio Emilia area treated with bDMARDS or tsDMARDS versus all residents: comparison among residents tested and residents positive for COVID-19 stratified by gender and classes of age

Residents of the Reggio Emilia area treated with bDMARDs or tsDMARDs
Total, nTested, nPositive, n
MaleFemaleTotalMaleFemaleTotalMaleFemaleTotal
Overall523672119581725369
Hospitalised4
Death1
Age
 ≤45143167310246000
 45–652673025693710336
 >66113203316369033
Drug mechanism of action
 Anti-TNF-alpha*33443677041317235
 Anti-IL-1†12719011011
 Anti-IL-6R‡145670000000
 Anti-IL-12/IL-23 anti-IL-23§412970101000
 Anti-IL-17°¶10385188224022
 Anti-JAK**143953112101
 Abatacept52025000000
All residents of the Reggio Emilia area
Total, nTested, nPositive, n
MaleFemaleTotalMaleFemaleTotalMaleFemaleTotal
Overall261 563270 328531 891340545427947169720493746
Hospitalised1342
Death383
Age
 ≤45133 037126 701259 73883513772212294453747
 45–6581 05782 183163 2401177151426916556911346
 >6647 46961 444108 9131393165130447489051653
  • *Etanercept, infliximab, adalimumab and their biosimilars, certolizumab pegol and golimumab.

  • †Anakirna and canakinumab.

  • ‡Tocilizumab and sarilumab.

  • §ustekinumab and guselkumab.

  • ¶Secukinumab, brodalumab and ixekizumab.

  • **Tofacitinib and baricitinib.

  • bDMARDs, biological disease-modifying antirheumatic drugs; tsDMARDs, targeted synthetic disease-modifying antirheumatic drugs.